dorzolamide/timolol / Generic mfg. - LARVOL DELTA

Acute Intraocular Pressure Elevation During Hemodialysis in a Patient with Glaucoma: A Case Highlighting the Need for Prompt Recognition and Surgical Intervention (NKF-SCM 2026) - "On admission, treatment was geared towards use of acetazolamide with increase in dosing until intraocular goal pressure is achieved...Maximal medical therapy (latanoprost, cosopt, brimonidine, pilocarpine, prednisolone, atropine) reduced IOP to 58 mmHg...Timely surgical intervention preserved eyesight and avoided delays in hemodialysis, emphasizing interdisciplinary management between nephrology and ophthalmology for at-risk patients. Intra-HD tonometry allowed us to ascertain the diagnosis, expedite surgery and monitor the efficacy of the surgical intervention."

Clinical • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Diabetic Nephropathy • Diabetic Retinopathy • Glaucoma • Hypertension • Immunology • Nephrology • Ophthalmology • Renal Disease • Respiratory Diseases • Retinal Disorders

Comparative safety and efficacy of brinzolamide/timolol and dorzolamide/timolol in the treatment of glaucoma patients: A systematic review and meta-analysis. (PubMed, Eur J Ophthalmol) - "Considering these findings, the choice of treatment usually depends on the patient's tolerance to higher initial ocular irritation in DT or blurring of vision in BT. Longer-term trials with 24-h IOP and preference are needed to assess these outcomes meaningfully."

Journal • Retrospective data • Review • Glaucoma • Ophthalmology

A Case Report of Carotid Cavernous Fistula: A Commonly Missed Diagnosis. (PubMed, J Educ Teach Emerg Med) - "Emergent surgical decompression was deferred due to chronicity of symptoms, and patient was started on dorzolamide/timolol and brimonidine eye drops as well as intravenous (IV) acetazolamide with subsequent improvement in IOP. This case is a good example of how non-traumatic causes of OCS can lead to misdiagnosis and how surgical decompression could potentially be deferred in subacute OCS. Ocular compartment syndrome, carotid cavernous fistula, eye pain, eye swelling, vision loss."

Journal • Achromatopsia • Ophthalmology • Pain

Real-World Transition to a Preservative-Free Fixed Combination of Dorzolamide/Timolol: Impact on the Ocular Surface Microenvironment, Safety, Tolerability, and Efficacy. (PubMed, Medicina (Kaunas)) - "Satisfaction regarding comfort (≥80%) and handling (≥50%) was high, with 88.0% preferring PF-DT. Transitioning to PF-DT improved ocular surface health while maintaining IOP control, supporting the benefits of preservative-free formulations in restoring microenvironment homeostasis and enhancing tolerability and patient satisfaction."

Journal • Real-world evidence • Dry Eye Disease • Glaucoma • Ophthalmology

Effect of prophylactic dorzolamide-timolol on intraocular pressure spikes following phacoemulsification. (PubMed, Can J Ophthalmol) - "Prophylactic dorzolamide-timolol reduces mean postoperative IOP and POD1 pressure spikes, independent of glaucoma comorbidities."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Peripapillary retinoschisis associated with open angle glaucoma responding to dorzolamide. (PubMed, Retin Cases Brief Rep) - "We present a case of peripapillary retinoschisis in a phakic patient that developed during treatment with a topical prostaglandin analogue. The schisis resolved after switching the prostaglandin analogue to a topical carbonic anhydrase inhibitor. We suggest that the prostaglandin may have had a role in initiating peripapillary retinoschisis associated with glaucomatous optic neuropathy and that carbonic anhydrase inhibitors are a potential treatment for this condition."

Journal • Glaucoma • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders

Combined procedure with Paul's glaucoma implant and reopening of previous filtering surgery in a patient with hypertensive uveitis crisis and juvenile glaucoma (SOE 2025) - "Hypotensive treatment was prescribed with a good response, but 1 week later she presented with the same condition, so oral acetazolamide was added.With the diagnosis of juvenile glaucoma + hypertensive uveitis crisis in the right eye, a complete laboratory work-up was performed with negative serology except for IgG VZV and IgG CMV which was positive...During the postoperative period she presented with hypertensive peaks requiring the following procedures: surgery to unknot the suture + partial removal of the tutor (7th week); complete removal of the tutor in consultation (9th week); topical dorzolamide-timolol and Molteno´s antifibrotic therapy for 6 weeks (3 weeks after removal of the tutor)...The coexistence of pre-existing juvenile glaucoma with an episode of severe, treatment-refractory hypertensive uveitis has not been described as a risk factor. Our hypothesis is that the trabecular meshwork, which has already been altered by juvenile glaucoma, is the target..."

Clinical • Surgery • Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

Cat scratch disease: ocular manifestations (SOE 2025) - "Initial therapy was Agapurin, Milgamma, Betaxolol drops and Nurofen...Dexamethasone, Dorzolamide, Timolol and Bromfenac eye drops were added... Cat scratch disease is an infectious illness primarily caused by the bacterium Bartonella henselae, commonly transmitted through scratches or bites from infected cats. While typically characterized by swollen lymph nodes, it can present with diverse range of symptoms. Ocular manifestations can serve as the sole or initial presentation of the disease."

Ophthalmology

Improvement of concomitant ocular surface disease in glaucoma patients after switching to a preservative-free fixed combination in a real-world transition context (SOE 2025) - "Purpose: To evaluate changes in ocular surface signs and symptoms and their impact on the efficacy of treatment for primary open-angle glaucoma (POAG) in patients with concomitant ocular surface disease (OSD) after switching from a preserved to a preservative-free Dorzolamide 2% + Timolol 0.5% (PF-DT). An experimental, prospective, single-arm, open-label, multicenter trial was conducted... It was demonstrated that switching from a preserved to a PF-DT formulation improved OSD signs and symptoms in patients with POAG, and this strengthened the hypotensive efficacy of the treatment."

Clinical • Real-world • Real-world evidence • Glaucoma • Ophthalmology

Hemodialysis and glaucoma (case report) (SOE 2025) - "A combined topical β-blocker and carbonic anhydrase inhibitor (Cosopt®) and a prostaglandin analog (Travatan®) were prescribed to both eyes when the intraocular pressure reached 38 and 34 mm Hg in the right and left eyes, respectively. Hemodialysis was performed routinely five times a week for 2 hours and 40 minutes using a central venous catheter. After failure of ocular treatment, glucose was administered intravenously (20% glucose 100 mL/h) during dialysis to prevent an increase in IOP."

Case report • Clinical • Cataract • Glaucoma • Ophthalmology

Intraoperative optical coherence tomography in glaucoma surgery with Ex-PRESS® implant. (PubMed, Eur J Ophthalmol) - "Our patient was being treated with dorzolamide-timolol eyedrops twice daily and bimatoprost eyedrops once daily in both eyes. I-OCT can help surgeons to locate the correct placement of implants in cases with media opacity (such as corneal opacification or gerontoxon) or in phakic patients, where it is important to avoid lens contact. This instrument is helpful in the training of ophthalmologists."

Journal • Cataract • Glaucoma • Ophthalmology

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Recruiting | Sponsor: Prairie Eye Center | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Investigating clues of cystoid macular edema from a vascular perspective under long-term latanoprost usage. (PubMed, Int Ophthalmol) - "This study demonstrates that latanoprost, the first prostaglandin analog known for its edema-inducing effect on the macula, does not have a long-term impact on macular vascularity. However, this result should be supported with longer and larger studies."

Journal • Glaucoma • Macular Edema • Ophthalmology

Drugs for open-angle glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Intravitreal Bevacizumab Alone Vs Combined With Topical Timolol-Dorzolamide or Dorzolamide for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. (PubMed, Clin Ophthalmol) - "Randomized controlled trials (RCTs) comparing IVB (1.25 mg, monthly) with topical dorzolamide-timolol (twice daily) or dorzolamide alone (twice daily) were included. Concurrent IVB with topical timolol-dorzolamide or dorzolamide alone demonstrated similar efficacy in improving BCVA and CMT in DME patients. However, the IVB+TD combination resulted in a more significant reduction in IOP compared to IVB alone."

Journal • Retrospective data • Review • Diabetes • Diabetic Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders

Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population. (PubMed, J Curr Glaucoma Pract) - "Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population. J Curr Glaucoma Pract 2024;18(4):137-141."

Journal • Glaucoma • Ophthalmology

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Not yet recruiting | Sponsor: Prairie Eye Center

New P4 trial • Glaucoma • Ophthalmology

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (clinicaltrials.gov) - P3 | N=51 | Terminated | Sponsor: Laboratorios Sophia S.A de C.V. | Trial completion date: Jun 2024 ➔ Oct 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2024 ➔ Oct 2024; Sponsor's prerogative since initial purpose for study shifted according to business strategy.

Head-to-Head • Trial completion date • Trial primary completion date • Trial termination • Glaucoma • Ophthalmology

Medicare Part D Glaucoma Drug Prescribing Patterns by Ophthalmologists from 2018 to 2022. (PubMed, J Ocul Pharmacol Ther) - "Prostaglandin analogues were the most frequently prescribed class, and the most commonly prescribed drugs were latanoprost, timolol, and the dorzolamide/timolol combination. An increasing number of claims annually, with the exception of the COVID-19 pandemic onset, reflects the growing prevalence of glaucoma. The utilization of new glaucoma agents, such as rho kinase inhibitors, is rapidly increasing as a new therapeutic option."

Journal • Medicare • Reimbursement • US reimbursement • Glaucoma • Infectious Disease • Novel Coronavirus Disease • Ophthalmology

Polydipsia Induced Acute Angle-Closure Crisis. (PubMed, J Glaucoma) - "He started topical brimonidine, dorzolamide 2%/timolol 0.5%, and latanoprost, and underwent phacoemulsification with placement of a posterior chamber intraocular lens (PCIOL) in the right eye. Several mechanisms of polydipsia induced AACC are proposed including choroidal expansion, increased sympathetic α-adrenergic tone, or differences in osmotic potential forces."

Journal • Cardiovascular • Heart Failure • Ophthalmology • Pain

Development and Evaluation of Polymethacrylate-Based Ophthalmic Nanofiber Inserts Containing Dual Drug-Loaded Dorzolamide and Timolol: In Vivo Study in Rabbit's Eye. (PubMed, Biomedicines) - "The cell compatibility test showed a high percentage of cell survival, and none of the formulations irritated the rabbit's eye. The Area Under the Curve (AUC0-72) for DOR and TIM in EDT formulations was approximately 3216.63 ± 63.25 µg·h/mL and 2598.89 ± 46.65 µg·h/mL, respectively, with Mean Residence Times (MRTs) of approximately 21.6 ± 0.19 h and 16.29 ± 6.44 h. Based on the results, the dual drug-loaded nanofiber preservative-free system can potentially be a suitable alternative to eye drops and can be used to reduce fluctuation and dose frequency."

Journal • Preclinical • Glaucoma • Ophthalmology

Simultaneous central retinal vein and cilioretinal artery occlusion in a young female patient with progestin-only oral contraceptive use: a case report. (PubMed, J Med Case Rep) - "This case highlights the rare presentation of simultaneous central retinal vein occlusion and cilioretinal artery occlusion, likely precipitated by short-term progestin-only OCP use in a young female. The absence of other vascular risk factors emphasizes the potential thrombotic risk associated with hormonal contraception, even in brief courses. Careful consideration should be given to contraceptive choice, and ophthalmologic monitoring is recommended for early detection and intervention in at-risk patients."

Journal • Cardiovascular • Hematological Disorders • Ophthalmology • Pain • Retinal Disorders • Venous Thromboembolism

Efficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide/timolol) in ocular hypertension and/or glaucoma. (PubMed, Int Ophthalmol) - "Generally, the PF dorzolamide/timolol combination was associated with a significant reduction in IOP and tolerability among glaucoma patients."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Randomized Clinical Trial of Intraocular Pressure-Lowering Medications on Preventing Spikes in Intraocular Pressure Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections. (PubMed, Ophthalmol Ther) - "Topical fixed combination anti-glaucoma medication used as a prophylactic treatment before intravitreal anti-VEGF injections significantly prevented IOP spikes post-injection, with a comparable effect among three medications. Prophylactic treatment of IOP spikes should be considered as standard care to prevent further damage in patients with compromised retinal vascular and optic nerve perfusion."

Clinical • Journal • Allergy • Glaucoma • Immunology • Ophthalmology • Retinal Disorders

Efficacy and Safety of a Fixed-Dose Combination of Brinzolamide 1%/Timolol 0.5% vs. Dorzolamide 2%/Timolol 0.5% in Indian Patients With Primary Open-Angle Glaucoma or Ocular Hypertension: A Randomized Phase 3 Study. (PubMed, Cureus) - "Fewer subjects in FDC brinzolamide/timolol group experienced ocular AEs as compared with FDC dorzolamide/timolol group (9.9% vs. 26.4%), especially ocular hyperemia (2.7% vs. 22.7%). Conclusion FDC of brinzolamide 1%/timolol 0.5% affords an ocular comfort advantage with a clinically meaningful reduction in IOP that was non-inferior to FDC of dorzolamide 2%/timolol 0.5% in Indian patients with POAG and ocular hypertension."

Journal • P3 data • Cardiovascular • Glaucoma • Ophthalmology